For the trial to resume, the FDA will require the biopharmaceutical company to disclose the infection that occurred on the consent form signed by trial participants, according to Reuters.
Several media outlets reported the infection to be a rare spinal disorder called transverse myelitis, an inflammation of the spinal cord that interrupts messages nerves send throughout the body.
U.K. health authorities resumed the trial after it found that there was not enough evidence to determine if the illness was caused by the vaccine.
The trial participant who was diagnosed with the disorder has been treated and discharged from a London hospital.
Pending regulatory approval, AstraZeneca plans to produce 2 billion doses of the vaccine, with 400 million to go to the U.S. and U.K.
More articles on spine:
A simple solution to the health insurance marketplace: Authorize interstate competition
Where orthopedic PE partnerships stand in 2020
Facet joint replacement, stem cells & AR: 9 surgeons discuss new technologies
